Investors

Download Event Supporting Material  NUCYNTA Acquisition Investor Presentation

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA®ER, NUCYNTA®, Gralise®, Cambia®, Lazanda® and Zipsor®. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential.Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform®, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed’s products:

NUCYNTA® ER (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

NUCYNTA® (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

Gralise® (gabapentin), a once-daily product for the management of postherpetic neuralgia, 

Cambia®(diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

Zipsor® (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for Gralise and the black box warnings for NUCYNTA ER, NUCYNTA, Cambia, Lazanda and Zipsor.

Recent News> MORE
DateTitle 
04/13/15Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing AppealPrinter Friendly Version
04/02/15Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) oral solution from Janssen Pharmaceuticals, Inc. for $1.05 billionPrinter Friendly Version
03/17/15Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen PharmaceuticalsPrinter Friendly Version
Upcoming and Recent Events> MORE
DateTitle
03/10/15
12:30 p.m. ET
Depomed at the 27th Annual ROTH Conference
LocationLaguna Niguel, CA
Supporting Materials
Download Event Supporting Material Depomed at the 27th Annual ROTH Conference Presentation
02/25/15
10:00 a.m. ET
Depomed at the RBC 2015 Healthcare Conference
LocationPalace Hotel
New York, NY
Supporting Materials
Download Event Supporting Material Depomed at the RBC 2015 Healthcare Conference Presentation
02/23/15
1:30 p.m. PT
Q4 2014 Depomed Earnings Conference Call
Supporting Materials
Download Event Supporting Material Depomed Q4 2014 Earnings Conference Transcript

DEPO (Common Stock)

Exchange
NASDAQ CM
Price
$27.65
Change (%)
 + 0.36 (1.32%)
Volume
1,121,831
Market Cap
$1,650,682,950

Data as of 04/24/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Powered By EDGAR Online, Inc.